Jonathan Richard
Psychiatric/Mental Health · North Chelmsford, MANPI 1124698766
Payments from drug & device makers
Across 148 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$907
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$621
- Lundbeck LLC$393
- Otsuka America Pharmaceutical, Inc.$284
- Johnson & Johnson$166
- Vanda Pharmaceuticals Inc.$142
- plus $427 from 7 others
What the payments were for
- Food & beverage$2,84797%
- Education$923%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $907 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 26 | $621 |
| Lundbeck LLC | 24 | $393 |
| Otsuka America Pharmaceutical, Inc. | 14 | $284 |
| Johnson & Johnson | 6 | $166 |
| Vanda Pharmaceuticals Inc. | 14 | $142 |
| Teva Pharmaceuticals USA, Inc. | 5 | $141 |
| E.r. Squibb & Sons, L.L.C. | 4 | $97 |
| Ironshore Pharmaceuticals Inc. | 2 | $59 |
| Alkermes, Inc. | 2 | $46 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Tempus AI, Inc | 1 | $28 |
| Corium, LLC | 1 | $25 |
How this compares
$2,939 in reported general payments places this provider in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
See all psychiatric/mental health providers in Massachusetts →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 37 | $59,094 |
| CaplytaLumateperone Tosylate | 16 | $40,938 |
| RexultiBrexpiprazole | 18 | $26,145 |
| Lurasidone Hcl | 16 | $7,172 |
| Lamotrigine ErLamotrigine | 27 | $6,130 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 43 | $1,293 |
| Oxcarbazepine | 25 | $1,176 |
| Lamotrigine | 61 | $1,042 |
| Gabapentin | 47 | $902 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 22 | $878 |
| Alprazolam | 59 | $747 |
| Aripiprazole | 53 | $733 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 47 | $725 |
| Clonazepam | 106 | $601 |
| Risperidone | 19 | $467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $907 | $59,09437 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $621 | $40,93816 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $284 | $26,14518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
Other psychiatric/mental health in North Chelmsford
- Henry KaggwaNorth Chelmsford$6K
- Grace RobertsonNorth Chelmsford$5K
- Brianne LienkampMarion$121K
- Ashley BakerQuincy$54K
- Brian BanksPembroke$47K
- Anne-Margaret BotelhoMattapoisett$46K
- Matthew PeculisWalpole$41K
- Sherrie UrenaWorcester$21K
- Irina DauphineeHanover$18K
- Schree PettigrewNew Bedford$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.